格隆汇12月15日丨轻松健康(02661.HK)发布公告，公司拟全球发售2654万股股份，中国香港发售股份 265.4万股，国际发售股份2388.6万股(以上可予重新分配及视乎超额配股权行使与否而定)；2025年12月 15日至12月18日招股；发售价将为每股发售股份22.68港元，股份将以每手200股股份买卖，中金公司及 招商证券国际为联席保荐人；预期股份将于2025年12月23日开始在联交所买卖。 按发售价为每股发售股份22.68港元计算(假设超额配股权未获行使)，全球发售所得款项净额将约为 5.134亿港元。集团拟将全球发售所得款项净额用于以下用途：约40.0%将用于提升集团的品牌知名度、 提高用户参与度及加强与业务合作伙伴的合作；约20.0%将用于医学研究和真实世界研究；约20.0%将 用于提升集团在AI及大数据领域的技术能力，以便更广泛应用于集团的产品及服务；约10.0%将用于拓 展至更多地区及海外市场；及约10.0%用作营运资金及其他一般公司用途。 集团于中国提供健康相关及保险相关解决方案。根据沙利文报告的资料，按2024年的收入计，集团于中 国数字综合健康服务及健康保险服务市场排名第10位。具体 ...

Core Viewpoint - QingSong Health Corporation is preparing for an IPO on the Hong Kong Stock Exchange, aiming to leverage its position as a leading provider of integrated health services and health insurance solutions in China [1][2]. Company Overview - QingSong Health Corporation is ranked 10th in China's digital integrated health services and health insurance market based on revenue for 2024, and 7th in the digital health services market [1][8]. - The company offers a variety of health-related services, including digital marketing, digital medical research support, comprehensive health service packages, and early disease screening promotion and consulting services [1][3]. Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue was approximately RMB 9.45 billion, with a net profit of about RMB 0.1 billion [1][5]. - The revenue for the first half of 2025 was RMB 6.56 billion, with a net profit of RMB 0.86 billion [1][5]. - The company has shown a compound annual growth rate (CAGR) of 54.95% in revenue from 2022 to 2025 [5]. User and Insurance Metrics - As of June 30, 2025, the company had 168.4 million registered users, with annualized premium income from sold insurance products totaling RMB 4.93 billion [2]. - The annualized premium income from sold insurance products has decreased from RMB 13 billion in 2022 to RMB 4.93 billion in 2025 [2]. Market Context - The market for digital integrated health services and health insurance in China is projected to grow from RMB 727 billion in 2020 to RMB 2,365 billion in 2024, with a CAGR of 34.3% [7]. - The market is expected to reach RMB 7,485 billion by 2029, with a projected CAGR of 25.9% from 2024 to 2029 [7]. Competitive Landscape - Comparable companies in the industry include Ping An Good Doctor, Health 160, and Health Road, with varying market capitalizations and financial metrics [11]. - QingSong Health Corporation's recent fiscal year revenue of RMB 9.45 billion positions it competitively within this landscape [11]. Management Structure - The board of directors consists of eight members, including two executive directors, three non-executive directors, and three independent non-executive directors [12]. Shareholder Structure - Major shareholders include Yang through various entities controlling 38.94% of voting rights, IDG China with 12.89%, and Sunshine Insurance with 10.56% [14]. Financing History - The company has undergone seven financing rounds, with the most recent raising approximately $75 million in December 2019 [15].